Latest Conference Articles

At the 2026 Horizons in Advanced Practice meeting, Omar Noor, MD, discussed viewing atopic dermatitis patients as type 2 inflammatory patients, growth curve data, and recent hidradenitis suppurativa guidelines.

The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.

SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.

Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.

Angela Fitch, MD, co-founder and chief medical officer of Knownwell, discussed GLP-1 access strategies and a proposed randomized trial in hidradenitis suppurativa at Fall Clinical 2026.

At Fall Clinical 2026, Joel Gelfand, MD, MSCE, reviewed GLP-1 candidacy, weight conversations, and an upcoming monotherapy trial in psoriasis.

A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.

At Fall Clinical 2026, Angela Fitch, MD, discussed GLP-1 prescribing by dermatologists and the metabolic and inflammatory link to psoriasis.

Joel Gelfand, MD, MSCE, discussed the role of GLP-1 agonists in addressing the metabolic comorbidities of psoriatic disease at Fall Clinical 2026.

At Fall Clinical 2026, Todd Schlesinger, MD, explained recent exosome regulatory progress, the remibrutinib label update for symptomatic dermographism, and ongoing clinical trials at his trial center.

Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.

Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.

In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.

Which vitiligo patients need oral vs topical JAK inhibitors? Iltefat Hamzavi, MD, shares his approach at Fall Clinical 2026.

Along with her Fall Clinical 2026 sessions, Glynis Ablon, MD, discusses combining energy devices with PRP and exosomes, early extended release minoxidil results, and topical stem cell research.

Todd Schlesinger, MD, highlighted the new photodynamic therapy indication for superficial basal cell carcinoma, immunotherapy options for cutaneous squamous cell carcinoma, and sequential actinic keratosis therapy at Fall Clinical 2026.

Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.

Two claims analyses of hidradenitis suppurativa showed similar symptom prevalence in males and females and lower dermatologist access among rural patients than urban patients.

At Fall Clinical 2026, Aaron Farberg, MD, reviewed gene expression profiling in atopic dermatitis and melanoma, and the Ameluz plus PDT approval for superficial basal cell carcinoma.

Adam Friedman, MD, discusses early psoriatic arthritis screening and why long-term data are critical to guiding treatment decisions.

At Fall Clinical 2026, Neal Bhatia, MD, discussed cycle therapy for actinic keratosis, red light photodynamic therapy for superficial basal cell carcinoma, and clinical research pitfalls

At Fall Clinical 2026, Jennifer Hsiao, MD, discussed patient preference, comorbidities, and access guide HS treatment selection.

Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.

In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.

Ahmad Naim, MD, discussed clinician education, long-term data, and what is next in alopecia areata, HS, and psoriasis.

At Fall Clinical 2026, Christopher Bunick, MD, PhD, discussed topical and oral acne management, including tetracycline selection and micronized isotretinoin.

At Fall Clinical 2026, Glynis Ablon, MD, recommends body dysmorphic disorder screening and systematic documentation in aesthetics, plus early combination therapy for multifactorial alopecia.

At Fall Clinical 2026, Shannon Trotter, DO, reviews locally advanced and metastatic cutaneous squamous cell carcinoma, immune checkpoint inhibitors, and proposed Medicare cuts affecting skin cancer care.